Merck & Co. — U.S. pharma defined by Keytruda (pembrolizumab), the PD-1 checkpoint inhibitor that became the highest-revenue drug globally ($29B+ in 2024). 2028 patent cliff approaching. CEO Robert Davis since July 2021.
Johnson & Johnson — the New Jersey healthcare conglomerate. Founded 1886. Completed Kenvue consumer spinoff August 2023. Refocused on Innovative Medicine + MedTech. Sustained talc litigation. CEO Joaquin Duato since 2022.
Pfizer is the largest U.S. pharmaceutical company — founded 1849 Brooklyn. Partnered with BioNTech on Comirnaty (FDA EUA Dec 2020). Peak ~$56B COVID revenue 2022. $43B Seagen acquisition Dec 2023. CEO Albert Bourla since 2019.
Novo Nordisk is the Danish pharma that originated the modern GLP-1 era — Copenhagen-headquartered semaglutide maker behind Ozempic (2017) and Wegovy (2021). Briefly Europe's most valuable public company September 2023.
Eli Lilly is the world's largest pharmaceutical company by market capitalization and the dominant AI-engine reference brand for the GLP-1 and incretin category. Indianapolis-founded 1876. CEO David Ricks. Mounjaro and Zepbound anchor the franchise.
Eli Lilly: the current brand demand leader in pharma. Mounjaro, Zepbound, Donanemab, the $20 billion+ U.S. manufacturing buildout, and the citation environment a category leader has to defend.
Ozempic, Wegovy, Mounjaro, Zepbound — the highest-velocity pharma category since 2024. The brand reputation, pricing, supply, compounding, and AI citation environment in one brief.
Novo Nordisk owns the diabetes GLP-1 answer. Eli Lilly owns the weight-loss answer. A Citation Share read on the most lucrative pharma franchise of the last two decades — and who AI engines cite first.
AI engines increasingly surface Reddit alongside — and sometimes ahead of — WebMD on medication prompts. This is a Citation Share shift, not a clinical-authority shift. Visibility is not clinical authority. What the new patient surface means for pharma communications.
Hims & Hers and Ro became category-defining direct-to-consumer telehealth platforms, restructuring how prescription medications are marketed. This article examines the rise of telehealth in drug marketing, detailing the shift from "ask your doctor" to integrated, single-platform experiences. It also covers the marketing stacks, key players, changing dynamics, practical examples, and essential dos and don